



**Australian Government**

---

**Department of Health and Aged Care**

**Fourth Report on Key Performance Measures (KPM)**

for the

**Seventh Community Pharmacy Agreement (7CPA)**

**May 2024**

## Contents

<b>Index of Tables</b> .....	<b>2</b>
<b>Introduction</b> .....	<b>3</b>
<b>Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians.</b> .....	<b>4</b>
a) Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).....	4
b) Transparency of charges (7CPA, Clause 4.3). .....	14
c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10). .....	15
d) Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4). .....	16
<b>Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies</b> .....	<b>17</b>
The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8). .....	17
<b>Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.</b> .....	<b>18</b>
a) Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14). .....	18
b) Accreditation of pharmacists for undertaking medication reviews.....	19
<b>Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines</b> .....	<b>21</b>
<b>Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas</b> .....	<b>23</b>

## Index of Tables

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies).....	5
Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies).....	5
Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies) .....	6
Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies) .....	6
Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies).....	6
Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies) .....	7
Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022 .....	8
Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022.....	9
Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2023 .....	10
Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies) .....	11
Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies).....	11
Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions .....	12
Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory .....	13
Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories* .....	15
Table 1(d): Total expenditure on Electronic Prescription Fees .....	16
Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid .....	17
Table 3(b)-1: Number and percentage of accredited registered pharmacists eligible to provide HMR and RMMR .....	19
Table 3(b)-2: Number and percentage of accredited pharmacists actively providing HMRs and RMMRs .....	20
Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services .....	21
Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance.....	22
Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services .....	24

## Introduction

Key Performance Measures (KPM) for the Seventh Community Pharmacy Agreement (7CPA) were developed as an evaluation framework for operation of the 7CPA. The KPM aim to enable Government, the pharmacy sector and the community to assess impacts of the 7CPA, based on the available evidence, and whether objectives and health outcomes have been achieved effectively and efficiently under the 7CPA.

The KPM were a new undertaking under the 7CPA. No other evaluation mechanisms had been developed under previous Community Pharmacy Agreements. As no specific funding was made available under the 7CPA for monitoring and evaluation, the KPM have been confined to measures that stem from existing processes, available data and resources, with no additional costs to Government.

The KPM were developed in collaboration between the Department and key stakeholders including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Consumers Health Forum of Australia, and the National Aboriginal Community Controlled Health Organisation.

KPM reports will be published on a biannual basis, subject to the availability of required data. The KPM will be reviewed in consultation with key stakeholders, named above.

Key objectives and outcomes to be monitored for the 7CPA are to:

1. Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians
2. Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies
3. Support professional initiatives for pharmacists to better fulfil their current scope of practice
4. Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines; and
5. Support access to medicines and pharmacy services for Australians in regional, rural, and remote areas.

This is the fourth KPM report, presenting information relevant to the following three six-month reporting periods under the 7CPA:

**1 January – 30 June 2022, 1 July – 31 December 2022, and 1 January – 30 June 2023.**

The information in this document should be read in conjunction with the [7CPA – Key Performance Measures and monitoring arrangements](#) and [Key Policy Principles – KPM for 7CPA](#), which are each available on the Department of Health and Aged Care's [website](#). Earlier KPM reports for the 7CPA can also be accessed at: <https://www.health.gov.au/resources/collections/7cpa-key-performance-measures>.

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians.

### a) ***Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).***

The following tables present information on:

- Total prescriptions and expenditure for s90 pharmacies<sup>1</sup>, for PBS and Repatriation Pharmaceutical Benefits Scheme (RPBS) items by patient category and state / territory – *Tables 1(a)-1, 1(a)-2, 1(a)-3, 1(a)-4, 1(a)-5, 1(a)-7, 1(a)-8 and 1(a)-9*
- Patient contribution and Government cost for PBS items dispensed by s90 pharmacies – *Table 1(a)-6*
- Over and under co-payment PBS prescriptions for items dispensed by s90 pharmacies – *Table 1(a)-2*
- Discounted and non-discounted PBS/RPBS items dispensed by s90 pharmacies – *Tables 1(a)-10 and 1(a)-11*
- PBS remuneration for s90 pharmacies and wholesalers – *Tables 1(a)-12*
- PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services – *Tables 1(a)-13*

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia. Data were extracted on 18 September 2023, unless otherwise indicated. Please note that:

- PBS data does not capture over-the-counter medicines, private prescriptions (non-PBS prescriptions) or public inpatient prescriptions.
- The figures provided are subject to change due to late claims and adjustments by pharmacies.

---

<sup>1</sup> ***“s90 Pharmacies”*** are those pharmacies operated by a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises. Other suppliers include approved doctors (usually practising in isolated areas) and approved hospitals.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies)**

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January - 30 June 2023	
	PBS Expenditure	Percentage	PBS Expenditure	Percentage	PBS Expenditure	Percentage
Section 85 - Concessional	\$3,166,222,454	59.2%	\$4,215,967,472	61.7%	\$3,452,204,383	56.4%
Section 85 - General	\$1,349,898,412	25.2%	\$1,694,704,288	24.8%	\$1,708,554,975	27.9%
Doctor's Bag	\$7,434,412	0.1%	\$27,535,152	0.4%	\$47,887,952	0.8%
Section 100	\$823,316,538	15.4%	\$897,956,183	13.1%	\$910,224,595	14.9%
<b>Total</b>	<b>\$5,346,871,816</b>	<b>100.0%</b>	<b>\$6,836,163,095</b>	<b>100.0%</b>	<b>\$6,118,871,906</b>	<b>100.0%</b>

Note: Excludes expenditure for RPBS items.

**Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January - 30 June 2023	
	PBS prescriptions	Percentage	PBS prescriptions	Percentage	PBS prescriptions	Percentage
Concessional Non-Safety Net	85,468,956	85.4%	45,073,721	39.3%	80,970,922	77.4%
Concessional Safety Net	5,811,228	5.8%	57,883,761	50.5%	12,205,843	11.7%
<b>Total Concessional</b>	<b>91,280,184</b>	<b>91.2%</b>	<b>102,957,482</b>	<b>89.8%</b>	<b>93,176,765</b>	<b>89.0%</b>
General Non-Safety Net	8,496,950	8.5%	8,456,664	7.4%	11,230,282	10.7%
General Safety Net	109,871	0.1%	3,124,599	2.7%	66,789	0.1%
<b>Total General</b>	<b>8,606,821</b>	<b>8.6%</b>	<b>11,581,263</b>	<b>10.1%</b>	<b>11,297,071</b>	<b>10.8%</b>
Doctors Bag	189,580	0.2%	175,503	0.2%	206,829	0.2%
<b>Total (Over Co-payment)</b>	<b>100,076,585</b>	<b>100.0%</b>	<b>114,714,248</b>	<b>100.0%</b>	<b>104,680,665</b>	<b>100.0%</b>
Under Co-payment scripts	50,797,169		52,647,856		51,438,263	
<b>Total (Over and Under Co-payment)</b>	<b>150,873,754</b>		<b>167,362,104</b>		<b>156,118,928</b>	

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Concessional Non-Safety Net	\$3,349,075,731	62.6%	\$2,233,738,862	32.7%	\$3,403,105,562	55.6%
Concessional Safety Net	\$230,839,429	4.3%	\$2,438,367,984	35.7%	\$499,948,714	8.2%
<b>Total Concessional</b>	<b>\$3,579,915,160</b>	<b>67.0%</b>	<b>\$4,672,106,846</b>	<b>68.3%</b>	<b>\$3,903,054,276</b>	<b>63.8%</b>
General Non-Safety Net	\$1,753,836,385	32.8%	\$1,965,442,682	28.8%	\$2,164,806,327	35.4%
General Safety Net	\$5,685,860	0.1%	\$171,078,416	2.5%	\$3,123,351	0.1%
<b>Total General</b>	<b>\$1,759,522,245</b>	<b>32.9%</b>	<b>\$2,136,521,098</b>	<b>31.3%</b>	<b>\$2,167,929,678</b>	<b>35.4%</b>
Doctors Bag	\$7,434,412	0.1%	\$27,535,152	0.4%	\$47,887,952	0.8%
<b>Total (Over Co-payment)</b>	<b>\$5,346,871,816</b>	<b>100.0%</b>	<b>\$6,836,163,095</b>	<b>100.0%</b>	<b>\$6,118,871,906</b>	<b>100.0%</b>

**Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)**

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage
Repatriation Non-Safety Net	3,073,958	90.9%	1,231,889	34.0%	2,751,960	82.5%
Repatriation Safety Net	309,208	9.1%	2,395,176	66.0%	582,780	17.5%
<b>Total Repatriation</b>	<b>3,383,166</b>	<b>100.0%</b>	<b>3,627,065</b>	<b>100.0%</b>	<b>3,334,740</b>	<b>100.0%</b>

**Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies)**

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Repatriation Non-Safety Net	\$122,278,592	91.0%	\$71,275,175	42.2%	\$122,069,789	83.8%
Repatriation Safety Net	\$12,153,585	9.0%	\$97,664,503	57.8%	\$23,658,202	16.2%
<b>Total Repatriation</b>	<b>\$134,432,177</b>	<b>100.0%</b>	<b>\$168,939,678</b>	<b>100.0%</b>	<b>\$145,727,991</b>	<b>100.0%</b>

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost
Concessional Non-Safety Net	\$559,827,415	\$3,349,075,731	\$293,847,652	\$2,233,738,862	\$569,560,783	\$3,403,105,562
Concessional Safety Net	\$0	\$230,839,429	\$0	\$2,438,367,984	\$0	\$499,948,714
<b>Total Concessional</b>	<b>\$559,827,415</b>	<b>\$3,579,915,160</b>	<b>\$293,847,652</b>	<b>\$4,672,106,846</b>	<b>\$569,560,783</b>	<b>\$3,903,054,276</b>
General Non-Safety Net	\$319,261,425	\$1,753,836,385	\$321,066,551	\$1,965,442,682	\$309,229,699	\$2,164,806,327
General Safety Net	\$715,408	\$5,685,860	\$20,529,445	\$171,078,416	\$444,541	\$3,123,351
<b>Total General</b>	<b>\$319,976,832</b>	<b>\$1,759,522,245</b>	<b>\$341,595,996</b>	<b>\$2,136,521,098</b>	<b>\$309,674,240</b>	<b>\$2,167,929,678</b>
<b>Total (excl. Drs Bag)</b>	<b>\$879,804,247</b>	<b>\$5,339,437,405</b>	<b>\$635,443,648</b>	<b>\$6,808,627,944</b>	<b>\$879,235,022</b>	<b>\$6,070,983,954</b>
Doctors Bag	\$0	\$7,434,412	\$0	\$27,535,152	\$0	\$47,887,952
<b>Total (Incl. Drs Bag)</b>	<b>\$879,804,247</b>	<b>\$5,346,871,816</b>	<b>\$635,443,648</b>	<b>\$6,836,163,095</b>	<b>\$879,235,022</b>	<b>\$6,118,871,906</b>

\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.



Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022**

*Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions*

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	27,646,960	21,153,765	17,831,256	7,204,947	7,929,709	2,497,069	307,620	897,630	85,468,956
<b>Concessional Safety Net</b>	2,027,964	1,383,481	1,214,205	464,795	473,066	175,704	8,494	63,519	5,811,228
<b>General Non-Safety Net</b>	2,815,800	1,972,755	1,770,277	527,445	952,411	190,529	79,876	187,857	8,496,950
<b>General Safety Net</b>	37,305	29,936	17,936	6,163	12,267	2,087	290	3,887	109,871
<b>Total</b>	<b>32,528,029</b>	<b>24,539,937</b>	<b>20,833,674</b>	<b>8,203,350</b>	<b>9,367,453</b>	<b>2,865,389</b>	<b>396,280</b>	<b>1,152,893</b>	<b>99,887,005</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,194,373,832	\$775,214,401	\$655,211,556	\$262,201,009	\$327,563,083	\$88,509,999	\$10,013,491	\$35,988,360	\$3,349,075,731
<b>Concessional Safety Net</b>	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
<b>General Non-Safety Net</b>	\$633,055,471	\$427,862,141	\$306,999,143	\$107,975,641	\$199,393,377	\$34,439,187	\$8,593,886	\$35,517,539	\$1,753,836,385
<b>General Safety Net</b>	\$1,885,601	\$1,663,153	\$879,478	\$276,014	\$676,624	\$123,137	\$8,974	\$172,877	\$5,685,860
<b>Total</b>	<b>\$1,908,932,349</b>	<b>\$1,260,235,086</b>	<b>\$1,009,988,437</b>	<b>\$388,848,919</b>	<b>\$547,744,603</b>	<b>\$130,402,667</b>	<b>\$18,904,754</b>	<b>\$74,380,592</b>	<b>\$5,339,437,405</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,374,013,730	\$917,339,909	\$770,264,510	\$309,818,159	\$379,276,348	\$104,654,845	\$11,589,534	\$41,946,112	\$3,908,903,146
<b>Concessional Safety Net</b>	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
<b>General Non-Safety Net</b>	\$735,855,407	\$508,393,270	\$370,035,337	\$128,410,173	\$235,473,742	\$41,209,843	\$10,744,544	\$42,975,493	\$2,073,097,810
<b>General Safety Net</b>	\$2,126,689	\$1,863,216	\$993,705	\$316,128	\$755,953	\$136,023	\$10,715	\$198,839	\$6,401,267
<b>Total</b>	<b>\$2,191,613,270</b>	<b>\$1,483,091,785</b>	<b>\$1,188,191,810</b>	<b>\$456,940,714</b>	<b>\$635,617,562</b>	<b>\$153,331,054</b>	<b>\$22,633,195</b>	<b>\$87,822,261</b>	<b>\$6,219,241,652</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (Section 85 and Section 100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022**

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	14,315,616	11,165,738	9,614,120	3,742,884	4,300,192	1,240,785	219,860	474,526	45,073,721
<b>Concessional Safety Net</b>	19,119,090	14,237,338	11,939,679	4,883,255	5,258,595	1,723,887	128,049	593,868	57,883,761
<b>General Non-Safety Net</b>	2,786,740	1,994,280	1,754,879	520,491	944,614	187,651	81,633	186,376	8,456,664
<b>General Safety Net</b>	1,057,261	761,460	568,022	206,699	362,108	67,013	10,049	91,987	3,124,599
<b>Total</b>	<b>37,278,707</b>	<b>28,158,816</b>	<b>23,876,700</b>	<b>9,353,329</b>	<b>10,865,509</b>	<b>3,219,336</b>	<b>439,591</b>	<b>1,346,757</b>	<b>114,538,745</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$831,704,665	\$501,275,722	\$429,938,453	\$167,315,936	\$219,417,010	\$52,966,741	\$8,182,341	\$22,937,993	\$2,233,738,862
<b>Concessional Safety Net</b>	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
<b>General Non-Safety Net</b>	\$715,714,696	\$487,108,477	\$339,475,811	\$120,715,366	\$215,484,030	\$37,874,265	\$10,180,168	\$38,889,869	\$1,965,442,682
<b>General Safety Net</b>	\$57,885,521	\$44,257,560	\$28,533,692	\$11,026,931	\$20,066,544	\$3,679,222	\$542,064	\$5,086,881	\$171,078,416
<b>Total</b>	<b>\$2,413,937,318</b>	<b>\$1,635,502,555</b>	<b>\$1,279,752,064</b>	<b>\$505,376,576</b>	<b>\$688,590,287</b>	<b>\$167,905,238</b>	<b>\$23,535,299</b>	<b>\$94,028,607</b>	<b>\$6,808,627,944</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$924,218,298	\$576,221,671	\$491,562,114	\$191,951,432	\$247,220,939	\$61,015,513	\$9,315,622	\$26,080,926	\$2,527,586,514
<b>Concessional Safety Net</b>	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
<b>General Non-Safety Net</b>	\$818,542,698	\$568,915,178	\$402,790,214	\$141,136,050	\$251,704,159	\$44,658,516	\$12,407,171	\$46,355,246	\$2,286,509,233
<b>General Safety Net</b>	\$64,786,270	\$49,378,892	\$32,184,496	\$12,396,594	\$22,457,887	\$4,104,916	\$597,062	\$5,701,744	\$191,607,860
<b>Total</b>	<b>\$2,616,179,701</b>	<b>\$1,797,376,536</b>	<b>\$1,408,340,933</b>	<b>\$551,802,418</b>	<b>\$755,005,686</b>	<b>\$183,163,955</b>	<b>\$26,950,582</b>	<b>\$105,251,779</b>	<b>\$7,444,071,591</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2023**

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	25,998,999	20,045,798	16,901,741	6,861,386	7,616,778	2,364,772	301,442	880,006	80,970,922
<b>Concessional Safety Net</b>	4,139,270	2,980,183	2,532,124	1,002,625	1,029,663	371,999	22,398	127,581	12,205,843
<b>General Non-Safety Net</b>	3,683,403	2,673,339	2,292,005	698,181	1,285,884	250,605	96,486	250,379	11,230,282
<b>General Safety Net</b>	24,083	18,713	10,610	3,555	6,284	1,132	236	2,176	66,789
<b>Total</b>	<b>33,845,755</b>	<b>25,718,033</b>	<b>21,736,480</b>	<b>8,565,747</b>	<b>9,938,609</b>	<b>2,988,508</b>	<b>420,562</b>	<b>1,260,142</b>	<b>104,473,836</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,232,052,373	\$777,337,490	\$662,968,007	\$264,234,685	\$331,660,060	\$87,782,110	\$10,160,052	\$36,910,784	\$3,403,105,562
<b>Concessional Safety Net</b>	\$169,840,476	\$121,691,671	\$100,813,485	\$40,841,636	\$44,433,708	\$15,745,527	\$782,223	\$5,799,990	\$499,948,714
<b>General Non-Safety Net</b>	\$788,058,992	\$532,041,162	\$379,747,847	\$132,488,086	\$237,428,949	\$42,245,534	\$10,635,226	\$42,160,529	\$2,164,806,327
<b>General Safety Net</b>	\$1,087,981	\$964,983	\$480,886	\$127,691	\$301,274	\$55,215	\$6,865	\$98,456	\$3,123,351
<b>Total</b>	<b>\$2,191,039,822</b>	<b>\$1,432,035,306</b>	<b>\$1,144,010,225</b>	<b>\$437,692,098</b>	<b>\$613,823,991</b>	<b>\$145,828,386</b>	<b>\$21,584,367</b>	<b>\$84,969,759</b>	<b>\$6,070,983,954</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,413,502,210	\$921,936,438	\$780,070,242	\$312,932,292	\$385,016,643	\$104,229,952	\$11,787,741	\$43,190,828	\$3,972,666,344
<b>Concessional Safety Net</b>	\$169,840,476	\$121,691,671	\$100,813,485	\$40,841,636	\$44,433,708	\$15,745,527	\$782,223	\$5,799,990	\$499,948,714
<b>General Non-Safety Net</b>	\$887,227,722	\$610,080,062	\$440,469,911	\$152,216,446	\$273,162,675	\$48,857,606	\$12,681,055	\$49,340,547	\$2,474,036,025
<b>General Safety Net</b>	\$1,246,581	\$1,096,405	\$547,396	\$150,795	\$342,176	\$62,917	\$7,880	\$113,742	\$3,567,892
<b>Total</b>	<b>\$2,471,816,989</b>	<b>\$1,654,804,576</b>	<b>\$1,321,901,034</b>	<b>\$506,141,169</b>	<b>\$702,955,201</b>	<b>\$168,896,001</b>	<b>\$25,258,898</b>	<b>\$98,445,107</b>	<b>\$6,950,218,976</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Prescription Type	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 January – 30 June 2022	Discounted	25,437,223	28%	2,704,488	31%	597,861	18%	28,739,572	28%
	Non-discounted	65,842,961	72%	5,902,333	69%	2,785,305	82%	74,530,599	72%
	<b>Grand Total</b>	<b>91,280,184</b>	<b>100%</b>	<b>8,606,821</b>	<b>100%</b>	<b>3,383,166</b>	<b>100%</b>	<b>103,270,171</b>	<b>100%</b>
1 July – 31 December 2022	Discounted	17,211,191	16.7%	3,349,610	28.9%	369,922	10.2%	20,930,723	17.7%
	Non-discounted	85,746,291	83.3%	8,231,653	71.1%	3,257,143	89.8%	97,235,087	82.3%
	<b>Grand Total</b>	<b>102,957,482</b>	<b>100.0%</b>	<b>11,581,263</b>	<b>100.0%</b>	<b>3,627,065</b>	<b>100.0%</b>	<b>118,165,810</b>	<b>100.0%</b>
1 January – 30 June 2023	Discounted	23,600,749	25.3%	3,366,076	29.8%	540,914	16.2%	27,507,739	25.5%
	Non-discounted	69,576,016	74.7%	7,930,995	70.2%	2,793,826	83.8%	80,300,837	74.5%
	<b>Grand Total</b>	<b>93,176,765</b>	<b>100.0%</b>	<b>11,297,071</b>	<b>100.0%</b>	<b>3,334,740</b>	<b>100.0%</b>	<b>107,808,576</b>	<b>100.0%</b>

**Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies)**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Discount Range	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 January – 30 June 2022	\$1.00	24,811,755	97.5%	2,666,561	98.6%	580,641	97.1%	28,058,957	97.6%
	0.50 - < \$1.00	378,805	1.5%	23,565	0.9%	9,574	1.6%	411,944	1.4%
	< 50c	108,113	0.4%	4,394	0.2%	3,635	0.6%	116,142	0.4%
	Other	138,550	0.5%	9,968	0.4%	4,011	0.7%	152,529	0.5%
	<b>Grand Total</b>	<b>25,437,223</b>	<b>100.0%</b>	<b>2,704,488</b>	<b>100.0%</b>	<b>597,861</b>	<b>100.0%</b>	<b>28,739,572</b>	<b>100.0%</b>
1 July – 31 December 2022	\$1.00	16,822,212	97.7%	3,293,732	98.3%	360,617	97.5%	20,476,561	97.8%
	0.50 - < \$1.00	249,293	1.4%	31,793	0.9%	5,700	1.5%	286,786	1.4%
	< 50c	59,870	0.3%	7,178	0.2%	1,586	0.4%	68,634	0.3%
	Other	79,816	0.5%	16,907	0.5%	2,019	0.5%	98,742	0.5%
	<b>Grand Total</b>	<b>17,211,191</b>	<b>100.0%</b>	<b>3,349,610</b>	<b>100.0%</b>	<b>369,922</b>	<b>100.0%</b>	<b>20,930,723</b>	<b>100.0%</b>
1 January – 30 June 2023	\$1.00	22,975,129	97.3%	3,274,999	97.3%	524,945	97.0%	26,775,073	97.3%
	0.50 - < \$1.00	385,018	1.6%	41,766	1.2%	9,430	1.7%	436,214	1.6%
	< 50c	111,915	0.5%	37,039	1.1%	3,607	0.7%	152,561	0.6%
	Other	128,687	0.5%	12,272	0.4%	2,932	0.5%	143,891	0.5%
	<b>Grand Total</b>	<b>23,600,749</b>	<b>100.0%</b>	<b>3,366,076</b>	<b>100.0%</b>	<b>540,914</b>	<b>100.0%</b>	<b>27,507,739</b>	<b>100.0%</b>

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to pharmacist for the purchase of medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

Expenses for PBS and RPBS Prescriptions	1 January – 30 June 2022	1 July – 31 December 2022	1 January – 30 June 2023
<b>Medicines Price</b>			
Ex-Manufacturer Price	\$4,205,920,812	\$5,145,138,722	\$4,817,893,119
Wholesale Mark-Up	\$225,682,221	\$274,719,201	\$252,374,026
<b>Total Price to Pharmacist</b>	<b>\$4,431,603,033</b>	<b>\$5,419,857,923</b>	<b>\$5,070,267,145</b>
<b>Pharmacy Costs</b>			
Administration, Handling and Infrastructure (AHI) fee	\$555,546,889	\$654,773,696	\$596,896,277
Dispensing Fee	\$797,892,501	\$916,693,173	\$835,975,364
Dangerous Drug Fee	\$19,834,830	\$21,644,848	\$22,521,556
Wastage Fee	\$3,080,697	\$3,438,981	\$3,441,854
Container Fee	\$516,403	\$426,710	\$375,963
<b>Total Pharmacy Remuneration</b>	<b>\$1,376,871,320</b>	<b>\$1,596,977,408</b>	<b>\$1,459,211,014</b>
<b>Total Cost</b>	<b>\$5,808,474,352</b>	<b>\$7,016,835,331</b>	<b>\$6,529,478,159</b>

Data is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory**

Report Period	RAHHS Supply	NSW/TAS*	NT	QLD	SA	WA	Australia
<b>1 January – 30 June 2022</b>	Total Items**	5,374	497,489	176,556	32,414	238,777	<b>950,610</b>
	Total Items Cost	\$132,617	\$12,942,427	\$5,197,948	\$888,138	\$5,872,765	<b>\$25,033,896</b>
	Individual Items***	1,645	338,080	108,388	14,298	141,558	<b>603,969</b>
	Individual Items cost	\$8,157	\$1,676,877	\$537,595	\$70,918	\$702,110	<b>\$2,995,656</b>
<b>1 July – 31 December 2022</b>	Total Items**	5,589	526,067	178,418	37,339	256,213	<b>1,003,626</b>
	Total Items Cost	\$142,727	\$13,970,658	\$5,331,177	\$1,015,595	\$6,679,525	<b>\$27,139,682</b>
	Individual Items***	1,526	353,627	113,685	16,278	177,843	<b>662,959</b>
	Individual Items cost	\$7,669	\$1,777,022	\$571,531	\$81,733	\$893,784	<b>\$3,331,739</b>
<b>1 January – 30 June 2023</b>	Total Items**	4,636	549,034	177,302	31,940	243,819	<b>1,006,731</b>
	Total Items Cost	\$112,367	\$14,529,994	\$4,766,765	\$922,122	\$6,394,415	<b>\$26,725,663</b>
	Individual Items***	1,445	368,460	104,098	14,858	151,171	<b>640,032</b>
	Individual Items cost	\$7,283	\$1,857,038	\$524,654	\$74,884	\$761,714	<b>\$3,225,574</b>

Note: there are no RAAHS data for VIC and ACT.

\* Data for NSW and Tasmania have been aggregated to prevent identification due to low number of individual data points available.

\*\* Total Items includes items supplied in bulk and individually.

\*\*\* Items supplied individually are taken from the no. of instances of the Patient Specific Medicine Supply Fee (PSMSF) paid for each PBS medicine ordered on a RAAHS prescription, and labelled for an individual patient, for supply through an approved RAAHS.

The PSMSF is paid in addition to the handling fee paid to eligible pharmacies for the supply of bulk PBS medicines to an approved RAAHS.

The PSMSF figures are a subset of the RAAHS figures.

From 1 July 2021 to 30 June 2022 the PSMSF was \$4.96 and from 1 July 2022 to 30 June 2023 is \$5.04.

The PSMSF data has been manually extracted from Services Australia Remote Area Aboriginal Health Services Access data base and is not sourced from official channels.

These data relate to the date claims are processed and may differ from other data provided by Services Australia, including PBS Expenditure data.

PSMSF values may be affected by rounding.

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### b) **Transparency of charges (7CPA, Clause 4.3).**

Clause 4.3 of the Seventh Community Pharmacy Agreement (7CPA) committed the Pharmacy Guild of Australia (Guild) to ensuring that Approved Pharmacists<sup>2</sup> “make consumers aware, prior to dispensing a Pharmaceutical Benefit, of any Safety Net Recording Fee and Additional Patient Charge to be charged, the fact that the Additional Patient Charge is not Commonwealth initiated, and the total cost to the consumer of that Pharmaceutical Benefit.” During the First Financial Year of the 7CPA, the Guild was required to work with the Department to develop arrangements and processes to support this commitment.

Following discussion at the first meeting of the 7CPA Pharmacy Stakeholder Consultation Committee (PSCC) in October 2020, the Guild worked with the Department to develop arrangements and processes for Approved Pharmacists to make the required disclosures and to notify consumers, prior to dispensing, of the price of the Pharmaceutical Benefit.

The draft communication resources and materials developed by the Guild, consisting of an in-pharmacy poster and supporting Frequently Asked Questions (FAQ), were subsequently discussed at the second PSCC meeting in April 2021, with further consultations between the Department, the Pharmaceutical Society of Australia (PSA), Consumers Health Forum of Australia (CHF) and the National Aboriginal Community Controlled Health Organisation (NACCHO), leading to consumer focus testing hosted by CHF and the Guild.

Following endorsement of the Guild’s communication resources by PSCC in July 2021, the resources were published on the Guild’s [FindaPharmacy](#) website on 1 January 2022, to coincide with annual PBS patient co-payment changes.

The Guild will continue to provide regular updates on progress and uptake of its PBS medicines pricing resources at biannual meetings of the PSCC. Communiqués arising from each meeting of the PSCC are published on the [Department’s website](#).

---

<sup>2</sup> An “**approved pharmacist**” means a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises.

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### c) **Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).**

The CTG PBS Co-payment program was established in July 2010 to improve access to affordable PBS medicines for Aboriginal and Torres Strait Islander people living with, or at risk of, chronic disease, and who in their doctor's opinion would experience setbacks in the prevention or ongoing management of chronic disease if they did not take the prescribed medicine and would be unlikely to adhere to their medicines regimen without assistance through the program.

When obtaining PBS General Schedule medicines at their local pharmacy, eligible general patients who would normally pay the full PBS co-payment pay the concessional rate and those eligible patients who would normally pay the concessional rate receive their PBS medicines without being required to pay a PBS co-payment.

The following table presents information on the total number of PBS items and expenditure for the CTG PBS Co-Payment Program across states and territories. This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

**Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories\***

Pharmacy State/Territory	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023**	
	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount
<b>ACT</b>	38,044	\$388,038	37,853	\$304,457	37,760	\$349,442
<b>NSW</b>	1,670,425	\$14,591,200	1,685,396	\$10,690,194	1,668,338	\$13,698,941
<b>NT</b>	112,822	\$1,066,306	117,191	\$920,885	120,518	\$1,070,568
<b>QLD</b>	1,310,573	\$11,514,246	1,330,385	\$8,762,770	1,317,597	\$10,928,872
<b>SA</b>	266,958	\$2,226,997	265,021	\$1,565,180	264,734	\$2,081,278
<b>TAS</b>	174,733	\$1,454,866	174,731	\$969,395	176,914	\$1,379,322
<b>VIC</b>	333,794	\$2,903,246	332,423	\$2,068,862	332,954	\$2,695,144
<b>WA</b>	442,403	\$3,927,907	442,448	\$3,015,821	442,309	\$3,686,398
<b>Total</b>	<b>4,349,752</b>	<b>\$38,072,805</b>	<b>4,385,448</b>	<b>\$28,297,565</b>	<b>4,361,124</b>	<b>\$35,889,965</b>

\* The data provided is inclusive of PBS and RPBS items and expenditure. \*\* Data extracted 28 September 2023.



## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### d) *Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).*

Electronic prescribing provides an option for prescribers and their patients to use an electronic prescription as an alternative to a paper prescription. Electronic prescriptions are part of the broader digital health and medicines safety framework and are part of an Australian Government budget measure to make the PBS more efficient. Electronic prescribing aims to provide convenience and choice to patients while improving PBS efficiency, compliance and medicines safety. Electronic prescribing does not fundamentally change existing prescribing and dispensing processes: patients can still choose which pharmacy they attend to fill their prescription; and paper prescriptions are still available.

An Electronic Prescription Fee (EPF) is paid to pharmacies for the dispensing of electronic prescriptions.

Under the 7CPA (clause 9.4), the Commonwealth continues to support the uptake of electronic prescriptions by Approved Pharmacists. Following the first financial year of the 7CPA, the EPF will transition to a direct funding arrangement with Exchange Infrastructure Providers rather than Approved Pharmacists.

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

**Table 1(d): Total expenditure on Electronic Prescription Fees**

Cost (PBS and RPBS Prescriptions)	1 January – 30 June 2022	1 July – 31 December 2022	1 January – 30 June 2023
Electronic Prescription Fee	\$9,705,446	\$11,724,385	\$11,140,845

## Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

### ***The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).***

Approved community pharmacy Access Points receive a payment of \$1 plus GST for each NDSS product pack supplied to registrants.

Community Service Obligation Distributors (CSODs) receive a payment of \$1 plus GST for each NDSS product pack delivered to NDSS Access Points.

**Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid**

Category	1 January – 30 June 2022	1 July – 31 December 2022	1 January – 30 June 2023
<b>Total No. of NDSS registrants</b>	1,454,169	1,487,300	1,451,094
<b>Registrants registered on the NDSS Gestational Diabetes Mellitus Reminder Register</b>	175,476	229,291	185,424
<b>Total No. of approved community pharmacy NDSS Access Points</b>	5,904	5,923	5,724
<b>Total Access Point Fees Paid</b>	<b>\$3,142,066</b>	<b>\$3,636,145</b>	<b>\$3,448,246</b>

## Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

### a) **Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).**

Clause 14.2 of the Seventh Community Pharmacy Agreement (7CPA) commits the Pharmaceutical Society of Australia (PSA) and the Department of Health and Aged Care, to working together in relation to the further development of the PSA Code of Ethics that underpins pharmacist practice in Australia.

The Department has chosen not to pursue an update of the PSA Code of Ethics at this time, following a review of PSA's proposal submitted in late 2021.

Clause 14.6 of the 7CPA commits the PSA to continue to maintain the Professional Practice Standards (PPS) and relevant clinical guidelines with the aim of providing pharmacists with practice information to support the safe and quality use of medicines.

As part of this work, the Department entered into a contract with PSA in October 2021, to redevelop the Guidelines for Medication Management for Aboriginal and Torres Strait Islander people. This was successfully completed and the redeveloped [Guidelines for Pharmacists supporting Aboriginal and Torres Strait Islander Peoples with Medicines Management](#) published in July 2022.

In April 2022, the Department entered into a contract with PSA to update the PPS. A draft version of the updated PPS was released for public consultation, which closed in March 2023. The updated PPS were launched at the PSA's PSA23 conference in July 2023 and published on the PSAs website: [Professional Practice Standards 2023 Version 6](#).

As part of this work, the PSA has also updated some clinical guidelines, including [Guidelines for the Continued Dispensing of Eligible Prescribed Medicines by Pharmacists](#), in August 2023.

## Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

### b) Accreditation of pharmacists for undertaking medication reviews

Home Medicines Reviews (HMR) and Residential Medication Management Reviews (RMMR) are medication management services initiated and supported by the Australian Government, aimed at supporting the quality use of medicines and assisting in minimising adverse medicine events by helping people understand and manage their medicines. Medication reviews are initiated by a medical practitioner and conducted by an accredited pharmacist. The HMR involves an accredited pharmacist making a home visit to a patient’s home to provide a medication review service, while the RMMR service is provided to an eligible patient residing in an eligible Residential Care Facility. In both HMR and RMMR, after the initial interview, the accredited pharmacist provides an HMR or RMMR report respectively to the initiating medical practitioner for consideration of issues raised.

From 21 April 2020, if clinically indicated, up to two follow-up services may be conducted to resolve medication-related problems identified at the initial interview.

**Table 3(b)-1: Number and percentage of accredited registered pharmacists eligible to provide HMR and RMMR**

Category	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Number	Percentage	Number	Percentage	Number	Percentage
Accredited registered pharmacists	2141 <sup>a</sup>	6.1%	2,836 <sup>c</sup>	7.9%	3207 <sup>e</sup>	8.8%
Total No. of registered pharmacists	35,368 <sup>b</sup>		35,732 <sup>d</sup>		36,425 <sup>f</sup>	

a - as at 31 October 2022. Information sourced from data published by [The Society of Hospital Pharmacists of Australia \(SHPA\)](#), [Australian Association of Consultant Pharmacy \(AACP\)](#) and [Pharmacy Board of Australia \(PBA\)](#).

b - as at 30 June 2022. Includes 642 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

c - as at 19 December 2022. Information sourced from data published by [The Society of Hospital Pharmacists of Australia \(SHPA\)](#), [The Accredited Pharmacist Issue 22/22](#) dated 19 December 2022 and [Pharmacy Board of Australia \(PBA\)](#).

d - as of 31 December 2022. Includes 125 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

e – as at 11 October 2023. Information sourced from PSA and data published by [SHPA Accredited Pharmacists Directory](#). Please note that the numbers reported are derived from opt-in directories and actual numbers may therefore differ from those shown in the table.

f – as at 30 June 2023. Information sourced from data published by [Pharmacy Board of Australia \(PBA\)](#).

Note: An accredited pharmacist can provide both HMR and RMMR services.

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice

**Table 3(b)-2: Number and percentage of accredited pharmacists actively providing HMRs and RMMRs**

	1 January – 30 June 2022		1 July – 31 December 2022		1 January - 30 June 2023	
Category	Number	Percentage	Number	Percentage	Number	Percentage
Average No. of accredited pharmacists actively providing HMR/RMMR services <sup>a</sup>	1,074	50.2%	1,250	44.1%	1,182	36.9%
Total No. of accredited pharmacists	2,141		2,836		3207	

*a - Information sourced from [7CPA - Pharmacy programs data](#) (last updated 24 October 2023) published by the Department of Health and Aged Care.*

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

## Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

The 7CPA provides funding for professional pharmacy programs and services over the life of the Agreement. These programs include continuation and revision of existing pharmacy programs and services from the 6CPA and include:

- **Medication Adherence Programs:** Dose Administration Aids (DAA) and Staged Supply
- **Medication Management Programs:** MedsCheck, Diabetes MedsCheck, Home Medicines Review (HMR), Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) in Residential Aged Care Facilities
- **Aboriginal and Torres Strait Islander Programs:** Indigenous Dose Administration Aids (IDAA) Program and Indigenous Health Services Pharmacy Support (IHSPS) Program

**Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services**

Program or Service	1 Jan – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Total Services	Expenditure	Total Services	Expenditure	Total Services	Expenditure
<b>Dose Administration Aids</b>	7,913,876	\$49,031,497	7,977,630	\$49,368,323	8,232,658	\$50,969,636
<b>Indigenous Dose Administration Aids</b>	842,841	\$9,950,898	903,094	\$10,577,216	975,535	\$11,482,991
<b>Staged Supply</b>	92,816	\$4,452,731	97,258	\$4,535,245	103,562	\$4,745,436
<b>HMR*</b>	58,477	\$11,167,055	79,891	\$14,732,760	64,607	\$12,597,906
<b>RMMR*</b>	68,856	\$6,759,048	80,010	\$7,857,906	75,875	\$7,463,484
<b>MedsCheck</b>	185,371	\$12,332,733	206,511	\$13,739,179	216,939	\$14,432,954
<b>Diabetes MedsCheck</b>	74,693	\$7,453,614	90,427	\$9,023,714	103,048	\$10,283,172
<b>Quality Use of Medicines in Residential Aged Care Facilities</b>	109 <sup>a</sup>	\$5,541,243	110 <sup>a</sup>	\$5,694,451	104 <sup>a</sup>	\$5,788,069

\* Total services for HMR and RMMR programs are inclusive of services paid for first and second follow up.

<sup>a</sup> – this item reports the average number of participating service providers for this service in any one month during the reporting period. Please note that it does not represent the number of services provided.

Information sourced from [7CPA - Pharmacy programs data](#) (last updated 24 October 2023) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

### Indigenous Health Services Pharmacy Support (IHSPS) Program

The IHSPS Program was created by merging the Quality Use of Medicines Maximised for Aboriginal & Torres Strait Islander People (QUMAX) and S100 Pharmacy Support Allowance programs, which continued from the 6CPA during the first year of the 7CPA (until 30 June 2021).

The IHSPS Program commenced in July 2021. Table 4-2 below shows the reduction in expenditure during the changeover from QUMAX and S100 Pharmacy Support Allowance programs to the IHSPS program.

**Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance**

Program	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure
QUMAX*	N/A	N/A	N/A	N/A	N/A	N/A
S100 Pharmacy Support Allowance*	N/A	N/A	N/A	N/A	N/A	N/A
IHSPS Program	225	\$1,103,667	228	\$2,584,282	224	\$1,194,096

\* Both QUMAX and S100 Pharmacy Support Allowance programs ceased as stand-alone programs on 30 June 2021. Expenditure for these programs recorded after this date represent payments for residual claims.

Information sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) (last updated 1 November 2023) published by the Department of Health and Aged Care.

*Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.*

## Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas

Rural Support Programs are targeted programs and services to support access to PBS medicines and pharmacy services for people living in regional, rural and remote regions of Australia. Services supported under the 7CPA include:

- Regional Pharmacy Maintenance Allowance
- Rural Continuing Professional Education Allowance
- Emergency Locum Service
- Intern Incentive Allowance for Rural Pharmacists
- Incentive Allowance for Rural Pharmacies- Extension Program
- Rural Intern Training Allowance
- Rural Pharmacy Scholarship Scheme
- Rural Pharmacy Scholarship Mentor Scheme
- Rural Pharmacy Liaison Officer Program
- Rural Pharmacy Student Placement Allowance Program and Administrative Support to Pharmacy Schools Scheme
- Aboriginal and Torres Strait Islander Pharmacy Scholarship Scheme

Table 5 (below) provides information on the number of participants and the total expenditure for each of the above programs.

Note that service providers differ based on specific programs and include pharmacists, pharmacy educators, universities and pharmacy interns, in addition to rural and remote hospital and community pharmacies.



Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

**Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services**

Program	1 January – 30 June 2022		1 July – 31 December 2022		1 January – 30 June 2023	
	Item	Expenditure	Item	Expenditure	Item	Expenditure
<b>Regional Pharmacy Maintenance Allowance (RPMA)*</b>	1061 <sup>a</sup>	\$9,893,154	1,079 <sup>a</sup>	\$9,888,853	1,092 <sup>a</sup>	\$9,916,475
<b>Rural Continuing Professional Education Allowance (CPE)</b>	68 <sup>b</sup>	\$67,536	76 <sup>b</sup>	\$76,468	132 <sup>b</sup>	\$141,129
<b>Emergency Locum Service (ELS)</b>	63 <sup>c</sup>	\$69,757	36 <sup>c</sup>	\$64,719	42 <sup>c</sup>	\$32,309
<b>Intern Incentive Allowance for Rural Pharmacies (IIARP)</b>	51.5 <sup>d</sup>	\$269,167	44.5 <sup>d</sup>	\$142,500	75 <sup>d</sup>	\$385,833
<b>Intern Incentive Allowance for Rural Pharmacies - Extension Program (IIRP-EP)</b>	9.5 <sup>d</sup>	\$70,000	8.5 <sup>d</sup>	\$71,667	11 <sup>d</sup>	\$92,500
<b>Rural Intern Incentive Allowance (RITA)</b>	21 <sup>b</sup>	\$11,572	73 <sup>b</sup>	\$36,663	62 <sup>b</sup>	\$30,885
<b>Rural Pharmacy Scholarship Scheme (RPSS)</b>	55 <sup>d</sup>	\$284,000	52 <sup>d</sup>	\$251,000	48 <sup>d</sup>	\$247,000
<b>Rural Pharmacy Scholarship Mentor Scheme (RPSMS)</b>	74 <sup>d</sup>	\$4,125	80.5 <sup>d</sup>	\$16,500	88 <sup>d</sup>	\$3,375
<b>Rural Pharmacy Liaison Officer (RPLO)</b>	9 <sup>d</sup>	\$193,500	9 <sup>d</sup>	\$355,500	9.5	\$330,600
<b>Rural Pharmacy Student Placement Allowance (RPSPA)</b>	16 <sup>e</sup>	\$219,132	16 <sup>e</sup>	\$273,819	17 <sup>e</sup>	\$82,838
<b>Administrative Support to Pharmacy Schools Scheme (ASPSS)</b>	16 <sup>e</sup>	\$95,469	16 <sup>e</sup>	\$117,500	17 <sup>e</sup>	\$102,985
<b>Aboriginal and Torres Strait Islander Pharmacy Scholarship Scheme (ATSIPSS)</b>	3.5 <sup>d</sup>	\$30,000	4 <sup>d</sup>	\$30,000	7 <sup>d</sup>	\$52,500

The items reported are; a-Average number of active service providers for RPMA, b- No. of approved claims, c- No. of locum placements, d- Average no. of active participants, e- Average no. of participating universities. This information was sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) (last updated 1 November 2023) published by the Department of Health and Aged Care.

\* This information was sourced from [7CPA - Pharmacy program data](#) (last updated 24 October 2023) published by the Department of Health and Aged Care.